| AO | Adverse outcome |
| AOP | Adverse outcome pathway |
| As | Arsenic |
| BKMR | Bayesian kernel machine regression |
| Cd | Cadmium |
| CI | Confidence interval |
| Cr(VI) | Hexavalent chromium |
| DIO1-3 | Iodothyronine deiodinases 1-3 |
| E1-E3 | Experimental modifier-evidence categories |
| fT3 | Free triiodothyronine |
| fT4 | Free thyroxine |
| GPX | Glutathione peroxidase |
| H1-H4 | Human modifier-evidence categories |
| HBM | Human biomonitoring |
| Hg | Mercury |
| HPT axis | Hypothalamic–pituitary–thyroid axis |
| KE | Key event |
| KER | Key-event relationship |
| MeHg | Methylmercury |
| MIE | Molecular initiating event |
| NIS | Sodium iodide symporter |
| Pb | Lead |
| Se | Selenium |
| SPINA-GD | Calculated peripheral deiodinase activity |
| SPINA-GT | Calculated thyroid secretory capacity |
| Sr | Strontium |
| T3 | Triiodothyronine |
| T4 | Thyroxine |
| Tg | Thyroglobulin |
| TH | Thyroid hormone |
| THSD | Thyroid hormone system disruption |
| TPO | Thyroid peroxidase |
| TSH | Thyroid-stimulating hormone |
| UIC | Urinary iodine concentration |